Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 18/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | GLA | P06280 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HBB | P68871 | 2/20 | 1.00 |
| ▸ | STAT6 | P42226 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | HNRNPA1 | P09651 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Camptothecin SCHEMBL6038 | 1.00 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL28057307 | 1.00 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL4304557 | 1.00 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL2298909 | 1.00 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL29351099 | 1.00 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL29369924 | 1.00 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL29360250 | 1.00 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL17112859 | 0.99 | TOP1 (0.98) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL6006531 | 0.99 | TOP1 (0.98) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL3117386 | 0.99 | TOP1 (0.98) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2854818-A2 | CHEMICAL SUPPRESSORS OF NEUROTOXICITY IN SYNUCLEINOPATHIC DISEASES | Oxalys Pharmaceuticals (CA) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013179144-A2 | CHEMICAL SUPPRESSORS OF NEUROTOXICITY IN SYNUCLEINOPATHIC DISEASES | OXALYS PHARMACEUTICALS (CA) | 2013-12-05 | — | — | WO | disclosed |
| EP-2616484-A2 | SCREENING METHOD | Universiteit Leiden (NL) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035120-A2 | SCREENING METHOD | UNIVERSITEIT LEIDEN (NL) | 2012-03-22 | — | — | WO | disclosed |
| WO-2008070858-A1 | INHIBITING TRANSLATION OF ABRERRANT DNMT3B TRANSCRIPTS IN CANCER CELLS USING INHIBITORY NUCLEIC ACIDS | UNIVERSITY OF CHICAGO (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2005082422-A1 | COMBINATION OF AD-P53 AND CHEMOTHERAPY FOR THE TREATMENT OF TUMOURS | INTROGEN THERAPEUTICS, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050170015-A1 | Antiproliferative colchicine compositions and uses thereof | CHEMGENEX PHARMACEUTICALS, INC. | 2005-08-04 | — | — | US | disclosed |
| EP-1330242-A2 | ANTIPROLIFERATIVE COLCHICINE COMPOSITIONS AND USES THEREOF | Chemgenex Therapeutics Inc. (US) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002056872-A2 | ANTIPROLIFERATIVE COLCHICINE COMPOSITIONS AND USES THEREOF | CHEMGENEX THERAPEUTICS, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-1991016904-A1 | METHOD FOR TREATING RETROVIRAL INFECTIONS IN MAMMALS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1991-11-14 | — | — | WO | disclosed |